TGV Therapeutics working with NIH on novel anti-fungal against deadly C.auris

Thursday, February 15, 2018

Early tests indicate effectiveness against dangerous new superbug fungus



(press release: den) // New York, NY, USA // Irene Johnson

TGV Therapeutics, the pharmaceutical company developing first-in-class drugs for fighting antibiotic-resistant infections, announced today it is working with the National Institutes of Health to expand its research on a drug that shows promise against new fungal superbugs.

TGV Therapeutics and its advisors, Dr. George and Victor Tetz, said initial data indicate their drug candidate, MYC-053, is effective against numerous emerging multidrug-resistant invasive fungal pathogens, including recent emerging threat -  Candida auris, which appears to spread in healthcare facilities.

The overall crude in-hospital mortality rate of C.auris candidemia ranges from 30% to 60%, and today it is one of the deadliest fungi. Anne Schuchat, former acting director of the CDC, has termed it a “catastrophic threat.”

MYC-053 is a structurally distinct both oral and IV antifungal antibiotic with a unique dual mode of action that shows promise in fighting a number of pathogenic fungi. After reviewing TGV’s application to conduct studies, the NIH connected the company with the number of research centers for expanded in-depth research.

“We are pleased that the NIH recognizes the potential of MYC-053 and the urgent need for expanded research and development of this groundbreaking drug,” said Haran Schlamm, a member of the scientific advisory board. “As we have seen with antibiotics, some strains of fungus are becoming increasingly resistant to the antifungal agents. And it is crucial we speed up research and testing of this drug to fight existing emerging multidrug-resistant species, as well as to avoid the spread of another dangerous fungi.”

###

About TGV-Therapeutics

TGV Therapeutics is a biopharmaceutical company committed to and developing novel antifungal antibiotics that will bring therapy of invasive fungal infections to a principally new level of effectiveness. TGV Therapeutics’ ultimate goal is to apply the MYC-053 to some of the deadliest fungal infections — those caused by multiresistant Candida species, including Candida glabrata and Candida auris

For more information about Victor and George Tetz and TGV Therapeutics, please contact Irene Johnson at (917) 477-7881, Email: Irene@thronepr.com